Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 19/20 | 0.60 |
| ▸ | TACR2 | P21452 | 8/20 | 0.60 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990828 | 1.00 | TACR3 (0.60) | TACR3TACR2TRPV4OPRM1CYP1A2 | |
| SCHEMBL4988606 | 0.87 | TACR3 (0.80) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4668092 | 0.87 | TACR3 (0.80) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4999506 | 0.87 | TACR3 (0.57) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4665598 | 0.87 | TACR3 (0.50) | TACR3TACR2TRPV4OPRM1 | |
| SCHEMBL4665600 | 0.86 | TACR3 (0.65) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL14090898 | 0.85 | TACR3 (0.59) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL4666997 | 0.85 | TACR3 (0.59) | TACR3TACR2OPRM1CYP1A2CYP3A4 | |
| SCHEMBL1581160 | 0.83 | TACR3 (0.77) | TACR3TACR2TRPV4OPRM1CYP1A2 | |
| SCHEMBL1581336 | 0.83 | TACR3 (0.77) | TACR3TACR2TRPV4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| EP-1891012-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006130080-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | claimed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| EP-1891012-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130080-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | KCNQ3, KCNA3, KCNK3 | TACR3 17/4885TACR2 22/4885TRPV4 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.